| Grab Key Company Sources And More: NXL Website. NXL Presentation. -----
And as I mentioned earlier, (Nasdaq: NXL) has several potential catalysts we're focusing on at the moment. Take a look:
#1. NXL Potential Catalyst - A Float This Size Could Create The Potential For Heightened Volatility In A Flash.
According to info from the Yahoo Finance website, NXL has a fairly low float.
In fact, the website reports this profile to have approximately 15.93Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
If the company provides more positive news towards the first part of 2026, could it help provide a breakout spark when paired with this volatility potential? -----
#2. NXL Potential Catalyst - The Company Launches Its AI-Driven Virtual Clinic "NeuroCare®," As Trial Also Leads To Official Launch Of Gen-3 Halo.
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
New digital heal-th platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-heal-th disorders
HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the launch of its new AI-designed virtual clinic platform, NeuroCare®, in collaboration with the University of California, San Diego. This marks the first step in deploying Nexalin’s digital heal-th ecosystem, designed to increase patient access, reduce costs, and provide long-term physician-patient care and monitoring across critical brain-heal-th indications. This collaboration builds upon Nexalin’s ongoing clinical research relationship with UC San Diego where patient enrollment has begun in trials evaluating Nexalin’s non-invasive Deep Intracranial Frequency Stimulation. This clinical trial marks the official launch of Nexalin’s new Gen-3 HALO™ headset that is now managed and monitored during treatment through the Nexalin NeuroCare® virtual clinic.
...
The NeuroCare digital platform is integrated with Nexalin’s next-generation Gen-3 HALO™ headset, which delivers improved Deep Intracranial Frequency Stimulation (“DIFS™”) in a home-based setting. The integration of the Gen-3 HALO system and NeuroCare creates a complete ecosystem—from remote physician oversight to advanced wearable therapy—for Alzheimer’s/dementia, mood disorders, and TBI/PTSD care. With the virtual clinic serving as the digital hub and the Gen-3 HALO device as the therapeutic delivery mechanism, Nexalin is positioning itself to scale beyond device sales into long-term recurring revenue, clinical data capture, and long-term patient retention. With initial deployment alongside UC San Diego’s clinical infrastructure, Nexalin expects the platform to serve as a cornerstone for scalable, data-driven revenue growth across global markets.
“Today we begin a new chapter in how brain-heal-th therapy is delivered,” said Mark White, CEO of Nexalin. “By launching our Gen-3 HALO neurostimulation system with the NeuroCare AI-designed virtual clinic platform, in partnership with UCSD, we remove the mental heal-th stigma, eliminate access barriers to treatment and lower the cost for patients and physicians alike. Nexalin is committed to building a foundation for a long-term relationship with its clients with recurring monthly subscriptions, long-term treatment adherence, and data-driven outcomes across Alzheimer’s, mood disorders, as well as active military and veteran-care applications. We believe this is a transformative step toward our vision of a full digital heal-th ecosystem for brain-heal-th.”
Read the full article here. -----
#3. NXL Potential Catalyst - The Company Highlights Critical Research Confirming Their Leadership In Evidenced-Based Non-Invasive Brain Stimulation.
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques
HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology across multiple neurological and psychiatric conditions. Currently, Nexalin is advancing its “mood-military-memory” clinical business plan with the FDA by publishing and submitting extensive clinical data.
Recent peer-reviewed and published data collectively span Insomnia and Depression (mood), traumatic brain injury and PTSD (military), Alzheimer’s disease (memory), and, most recently, attention deficit hyperactivity disorder (ADHD). Together, this body of clinical evidence continues to support Nexalin’s clinical business plan presented in recent pre-submission meetings with the FDA.
Nexalin’s growing body of published data consistently demonstrates objective normalization of abnormal brain activity and network function. This normalization of abnormal brain function is validated through traditional patient symptom surveys, advanced neuroimaging, and other bioelectrical biomarkers administered pre- and post-treatment.
...
“Across multiple independent studies, we are not just observing that patients feel better—we are seeing measurable changes in how the brain functions," said Mark White, CEO of Nexalin Technology. “That distinction matters. Nexalin is a powerful whole-brain neurostimulation medical device that evidence indicates can penetrate deep in the brain to dramatically increase positive treatment response. Nexalin is not another battery-operated internet device sold to consumers. Our DIFS™ technology is designed to regulate abnormal neural signaling and normalize disrupted brain networks, and we have objective imaging data to support that mechanism.”
...
Read the full article here. -----
#4. NXL Potential Catalyst - Engagement With The FDA Provides Clearer And More Collaborative Path Forward For Company's Alzheimer’s Program.
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease
HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting with the U.S. Food and Drug Administration (“FDA”) regarding its Gen-2 SYNC™ neurostimulation console for the treatment of Alzheimer’s disease.
The meeting focused on Nexalin’s proposed clinical development plan and overall regulatory strategy for the Gen-2 SYNC console in Alzheimer’s disease. As part of the interaction, the Company and the FDA discussed the potential use of the De Novo classification pathway for this indication, reflecting the novel mechanism of action of Nexalin’s deep, frequency-specific neurostimulation technology.
The discussion provided a clear understanding of Nexalin’s existing clinical data for the treatment of Alzheimer’s disease. Additional discussions included Nexalin’s plans for new U.S.-based Pilot Studies, followed by a large pivotal study designed to demonstrate the safety and efficacy of the Gen-2 SYNC console in patients with mild to moderate Alzheimer’s disease. Key topics included the design of both the pilot and pivotal trials, with alignment reached on foundational components such as patient population, dosing paradigm, and elements of the statistical analysis plan.
Importantly, Nexalin and the FDA also reviewed appropriate primary and secondary endpoints to measure clinically meaningful outcomes in Alzheimer’s disease, including standardized cognitive assessments, PET scans, blood tests and functional imaging. The feedback from the Q-Sub meeting will be used in support Nexalin’s upcoming clinical protocol and Investigational Device Exemption (IDE) submission in the United States.
“This constructive engagement with the FDA is critical and provides us with a clearer and more collaborative path forward for our Alzheimer’s program,” said Mark White, CEO of Nexalin Technology. “We are encouraged by the dialogue and by feedback consistent with a De Novo regulatory pathway, which underscores the novelty of our approach. The clarity gained around primary and secondary endpoints allows us to finalize a robust pilot and pivotal study design, bringing us one step closer to offering a safe, non-invasive, drug-fr-ee therapeutic option for the millions of patients and families impacted by this devastating disease.”
...
Read the full article here. -----
#5. NXL Potential Catalyst - A Maxim Group Analyst Tags NXL With A $4 Target.
The Maxim Group has built one of the premier proprietary research platforms on Wall Street, with an emphasis on small-cap, micro-cap, and emerging growth companies.
Anthony Vendetti, a senior heal-thcare analyst at Maxim Group covering the biotechnology sector, has suggested a $4.00 target for Nexalin Technology as of 2/23/25 according to published info on the company’s website.
With this $4.00 target, there could be upside potential of over 650% for NXL from its closing valuation Monday. -----
(Nasdaq: NXL) Recap - 5 Potential Catalysts Lead The Way
#1. A Float This Size Could Create The Potential For Heightened Volatility In A Flash.
#2. The Company Launches Its AI-Driven Virtual Clinic "NeuroCare®," As Trial Also Leads To Official Launch Of Gen-3 Halo.
#3. The Company Highlights Critical Research Confirming Their Leadership In Evidenced-Based Non-Invasive Brain Stimulation.
#4. Engagement With The FDA Provides Clearer And More Collaborative Path Forward For Company's Alzheimer’s Program.
#5. A Maxim Group Analyst Tags NXL With A $4 Target. -----
Coverage is now officially underway for Nexalin Technology, Inc. (Nasdaq: NXL).
Be on the lookout for updates coming out shortly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/23/2026 and ending on 02/24/2026 to publicly disseminate information about (NXL:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). These Funds were part of the seventy seven thousand five hundred USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (NXL:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/nxl-2uade/#details | 
Tidak ada komentar:
Posting Komentar